Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia

Takuji Yamauchi, Yasuo Mori, Toshihiro Miyamoto, Kenjiro Kamezaki, Takatoshi Aoki, Asataro Yamamoto, Katsuto Takenaka, Hiromi Iwasaki, Naoki Harada, Koji Nagafuji, Takanori Teshima, Koichi Akashi

Research output: Contribution to journalArticlepeer-review

Abstract

Gemtuzumab ozogamicin (GO) is an effective molecular-targeted agent for CD33-positive acute myelogenous leukemia (AML) patients who are resistant to conventional chemotherapy. Recent prospective trials have revealed the safety and efficacy of GO as part of conditioning following allogeneic bone marrow or peripheral blood stem cell transplantation (SCT). We report here for the first time three AML cases that relapsed after allogeneic SCT and underwent unrelated cord blood transplantation (UCBT) following reduced-intensity conditioning (RIC) comprising fludarabine, melphalan, and low-dose total body irradiation combined with GO. Primary neutrophil engraftment occurred in all cases, while recovery of platelet count was delayed. Only one case of reversible hepatic sinusoidal obstruction syndrome was documented. Non-relapse mortality at day 100 was not documented. Notably, one patient who responded to GO survived for 6 months after UCBT in remission with excellent performance status, while the remaining cases relapsed early. These data suggest that GO may be safely combined with RIC for UCBT after previous allogeneic SCT.

Original languageEnglish
Pages (from-to)416-420
Number of pages5
JournalInternational journal of hematology
Volume90
Issue number3
DOIs
Publication statusPublished - Oct 2009

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this